{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:09:01Z","timestamp":1790096941316,"version":"4.0.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004441","name":"Styrelsen f\u00f6r Internationellt Utvecklingssamarbete","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004441","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007042","name":"The Academy of Sciences for the Developing World","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.drudis.2026.104784","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T06:22:19Z","timestamp":1787552539000},"page":"104784","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biochemical aspects of chromatin-modifying drugs"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9393-9516","authenticated-orcid":false,"given":"Meran Keshawa","family":"Ediriweera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmila","family":"Jayasena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104784_b0005","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41392-024-02039-0","article-title":"Epigenetics-targeted drugs: current paradigms and future challenges","volume":"9","author":"Dai","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.drudis.2026.104784_b0010","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1146\/annurev-pharmtox-061008-103102","article-title":"Epigenetics, DNA methylation, and chromatin modifying drugs","volume":"49","author":"Szyf","year":"2009","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.drudis.2026.104784_b0015","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/febs.15966","article-title":"Therapeutic targeting of chromatin: status and opportunities","volume":"289","author":"Siklos","year":"2022","journal-title":"FEBS J"},{"key":"10.1016\/j.drudis.2026.104784_b0020","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1016\/j.cell.2021.05.029","article-title":"Reading the chromatinized genome","volume":"184","author":"Michael","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2026.104784_b0025","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nrc3068","article-title":"SWI\/SNF nucleosome remodellers and cancer","volume":"11","author":"Wilson","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.drudis.2026.104784_b0030","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41576-022-00468-7","article-title":"Histone post-translational modifications \u2013 cause and consequence of genome function","volume":"23","author":"Mill\u00e1n-Zambrano","year":"2022","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.drudis.2026.104784_b0035","doi-asserted-by":"crossref","first-page":"e292","DOI":"10.1002\/mco2.292","article-title":"Post-translational modifications of histones: mechanisms, biological functions, and therapeutic targets","volume":"4","author":"Liu","year":"2023","journal-title":"MedComm (2020)"},{"key":"10.1016\/j.drudis.2026.104784_b0040","doi-asserted-by":"crossref","DOI":"10.4061\/2010\/920161","article-title":"H2AX phosphorylation: its role in DNA damage response and cancer therapy","volume":"2010","author":"Podhorecka","year":"2010","journal-title":"J Nucleic Acids"},{"key":"10.1016\/j.drudis.2026.104784_b0045","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3390\/cells8091034","article-title":"H3K4me3, H3K9ac, H3K27ac, H3K27me3 and H3K9me3 histone tags suggest distinct regulatory evolution of open and condensed chromatin landmarks","volume":"8","author":"Igolkina","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.drudis.2026.104784_b0050","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.apsb.2013.04.007","article-title":"Epigenetic modification enzymes: catalytic mechanisms and inhibitors","volume":"3","author":"Lu","year":"2013","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.drudis.2026.104784_b0055","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1021\/acs.biochem.5b01210","article-title":"Role of histone-modifying enzymes and their complexes in regulation of chromatin biology","volume":"55","author":"DesJarlais","year":"2016","journal-title":"Biochemistry"},{"key":"10.1016\/j.drudis.2026.104784_b0060","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S0955-0674(03)00013-9","article-title":"Histone and chromatin cross-talk","volume":"15","author":"Fischle","year":"2003","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.drudis.2026.104784_b0065","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.chembiol.2014.07.024","article-title":"Small molecule control of chromatin remodeling","volume":"21","author":"Finley","year":"2014","journal-title":"Chem Biol"},{"key":"10.1016\/j.drudis.2026.104784_b0070","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41589-021-00920-5","article-title":"Small molecule targeting of chromatin writers in cancer","volume":"18","author":"Conery","year":"2022","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.drudis.2026.104784_b0075","doi-asserted-by":"crossref","DOI":"10.2217\/epi-2023-0443","article-title":"Current trends in clinical trials and the development of small molecule epigenetic inhibitors as cancer therapeutics","author":"Zohourian","year":"2024","journal-title":"Epigenomics"},{"key":"10.1016\/j.drudis.2026.104784_b0080","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1038\/s12276-023-01117-7","article-title":"Tumor-suppressive functions of protein lysine methyltransferases","volume":"55","author":"Aziz","year":"2023","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.drudis.2026.104784_b0085","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","article-title":"Chromatin modifications and their function","volume":"128","author":"Kouzarides","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2026.104784_b0090","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1021\/acs.chemrev.8b00008","article-title":"Chemical and biochemical perspectives of protein lysine methylation","volume":"118","author":"Luo","year":"2018","journal-title":"Chem Rev"},{"key":"10.1016\/j.drudis.2026.104784_b0095","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.3390\/ijms20133322","article-title":"The biological axis of protein arginine methylation and asymmetric dimethylarginine","volume":"20","author":"Fulton","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104784_b0100","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1139\/bcb-2023-0212","article-title":"Protein arginine methyltransferase 1, a major regulator of biological processes","volume":"102","author":"Sudhakar","year":"2023","journal-title":"Biochem Cell Biol"},{"key":"10.1016\/j.drudis.2026.104784_b0105","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.2217\/fon-2020-1244","article-title":"EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed\/refractory follicular lymphoma","volume":"17","author":"Julia","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.drudis.2026.104784_b0110","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1016\/j.celrep.2019.10.083","article-title":"Targeting excessive EZH1 and EZH2 activities for abnormal histone methylation and transcription network in malignant lymphomas","volume":"29","author":"Yamagishi","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.drudis.2026.104784_b0115","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nsmb.1560","article-title":"Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294","volume":"16","author":"Chang","year":"2009","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.drudis.2026.104784_b0120","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1182\/blood-2013-04-497644","article-title":"Potent inhibition of DOT1L as treatment of MLL-fusion leukemia","volume":"122","author":"Daigle","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2026.104784_b0125","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1182\/blood-2017-12-818948","article-title":"The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2026.104784_b0130","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1021\/acsmedchemlett.6b00168","article-title":"Optimization of a fragment-based screening hit toward potent DOT1L inhibitors interacting in an induced binding pocket","volume":"7","author":"Scheufler","year":"2016","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.drudis.2026.104784_b0135","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ijc.23607","article-title":"Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine","volume":"123","author":"Stresemann","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.drudis.2026.104784_b0140","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/pros.21247","article-title":"Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth","volume":"71","author":"Lin","year":"2011","journal-title":"Prostate"},{"key":"10.1016\/j.drudis.2026.104784_b0145","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026831","article-title":"HDACs and HDAC inhibitors in cancer development and therapy","volume":"6","author":"Li","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.drudis.2026.104784_b0150","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1073\/pnas.0430973100","article-title":"Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation","volume":"100","author":"Haggarty","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2026.104784_b0155","doi-asserted-by":"crossref","first-page":"13459","DOI":"10.1073\/pnas.1718823114","article-title":"Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors","volume":"114","author":"Porter","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2026.104784_b0160","doi-asserted-by":"crossref","first-page":"15064","DOI":"10.1073\/pnas.0404603101","article-title":"Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor","volume":"101","author":"Vannini","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2026.104784_b0165","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/ja.2011.35","article-title":"Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma","volume":"64","author":"VanderMolen","year":"2011","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.drudis.2026.104784_b0170","article-title":"NBM-T-L-BMX-OS01, semisynthesized from osthole, is a novel inhibitor of histone deacetylase and enhances learning and memory in rats","volume":"2013","author":"Yang","year":"2013","journal-title":"Evid Based Complement Alternat Med"},{"key":"10.1016\/j.drudis.2026.104784_b0175","unstructured":"ClinicalTrials.gov. A safety and pharmacokinetic study of NBM-BMX administered orally to patients with advanced cancer. (NCT03726294). https:\/\/clinicaltrials.gov\/study\/NCT03726294#study-record-dates."},{"key":"10.1016\/j.drudis.2026.104784_b0180","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/ardp.201100209","article-title":"Small molecule inhibitors of histone acetyltransferases as epigenetic tools and drug candidates","volume":"345","author":"Furdas","year":"2012","journal-title":"Arch Pharm (Weinheim)"},{"key":"10.1016\/j.drudis.2026.104784_b0185","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nature24028","article-title":"Discovery of a selective catalytic p300\/CBP inhibitor that targets lineage-specific tumours","volume":"550","author":"Lasko","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104784_b0190","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.chembiol.2010.03.006","article-title":"Virtual ligand screening of the p300\/CBP histone acetyltransferase: identification of a selective small molecule inhibitor","volume":"17","author":"Bowers","year":"2010","journal-title":"Chem Biol"},{"key":"10.1016\/j.drudis.2026.104784_b0195","doi-asserted-by":"crossref","DOI":"10.3389\/freae.2025.1594400","article-title":"Discovery and structural studies of histone demethylases","volume":"3","author":"Peng","year":"2025","journal-title":"Front Epigenet Epigenomics"},{"key":"10.1016\/j.drudis.2026.104784_b0200","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.1021\/bi0618621","article-title":"trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1","volume":"46","author":"Schmidt","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.drudis.2026.104784_b0205","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1158\/2767-9764.CRC-24-0296","article-title":"Seclidemstat (SP-2577) induces transcriptomic reprogramming and cytotoxicity in multiple fusion-positive sarcomas","volume":"5","author":"Rask","year":"2025","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.drudis.2026.104784_b0210","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/s41401-024-01439-w","article-title":"Discovery of novel dual-target inhibitors of LSD1\/EGFR for non-small cell lung cancer therapy","volume":"46","author":"Wei","year":"2025","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.drudis.2026.104784_b0215","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3390\/biomedicines13030594","article-title":"A minireview on BET inhibitors: beyond bromodomain targeting","volume":"13","author":"Iudin","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.drudis.2026.104784_b0220","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104784_b0225","doi-asserted-by":"crossref","first-page":"8857","DOI":"10.1038\/s41598-017-08909-8","article-title":"Selective inhibition mechanism of RVX-208 to the second bromodomain of bromo and extraterminal proteins: insight from microsecond molecular dynamics simulations","volume":"7","author":"Wang","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2026.104784_b0230","doi-asserted-by":"crossref","first-page":"30208","DOI":"10.1074\/jbc.M103604200","article-title":"p65-activated histone acetyltransferase activity is repressed by glucocorticoids: mifepristone fails to recruit HDAC2 to the p65-HAT complex","volume":"276","author":"Ito","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2026.104784_b0235","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1007\/s12672-025-03635-4","article-title":"Genetic and epigenetic contribution to tamoxifen resistance in breast cancer, concepts to drive therapeutic strategies","volume":"16","author":"Jahangiri","year":"2025","journal-title":"Discov Oncol"},{"key":"10.1016\/j.drudis.2026.104784_b0240","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nm.3788","article-title":"Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia","volume":"21","author":"Chan","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2026.104784_b0245","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1158\/2159-8290.CD-16-1034","article-title":"AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations","volume":"7","author":"Yen","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.drudis.2026.104784_b0250","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1126\/science.1234769","article-title":"Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation","volume":"340","author":"Wang","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.drudis.2026.104784_b0255","doi-asserted-by":"crossref","first-page":"49504","DOI":"10.1074\/jbc.M207836200","article-title":"Arsenic trioxide promotes histone H3 phosphoacetylation at the chromatin of CASPASE-10 in acute promyelocytic leukemia cells","volume":"277","author":"Li","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2026.104784_b0260","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.bbrc.2015.11.063","article-title":"H3S10 phosphorylation-mediated transcriptional regulation by Aurora kinase A","volume":"469","author":"Kim","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2026.104784_b0265","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.biocel.2008.08.027","article-title":"Acetylation of non-histone proteins modulates cellular signalling at multiple levels","volume":"41","author":"Spange","year":"2009","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.drudis.2026.104784_b0270","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/annonc\/mdx157","article-title":"BET inhibitors: a novel epigenetic approach","volume":"28","author":"Doroshow","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drudis.2026.104784_b0275","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1126\/science.aab1433","article-title":"Drug development. Conjugation as a strategy for in vivo target protein degradation","volume":"348","author":"Winter","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.drudis.2026.104784_b0280","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1186\/s13059-014-0406-2","article-title":"DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML","volume":"15","author":"Lund","year":"2014","journal-title":"Genome Biol"},{"key":"10.1016\/j.drudis.2026.104784_b0285","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1016\/j.celrep.2017.11.095","article-title":"BET bromodomain inhibition synergizes with PARP inhibitor in epithelial ovarian cancer","volume":"21","author":"Karakashev","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.drudis.2026.104784_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103569","article-title":"Fatty acids as histone deacetylase inhibitors: old biochemistry tales in a new life sciences town","volume":"28","author":"Ediriweera","year":"2023","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104784_b0295","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1111\/bph.16237","article-title":"Natural products modulating epigenetic mechanisms by affecting histone methylation\/demethylation: targeting cancer cells","volume":"182","author":"Dorna","year":"2025","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.drudis.2026.104784_b0300","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.atherosclerosis.2016.01.036","article-title":"RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I\/HDL and represses pathways that contribute to cardiovascular disease","volume":"247","author":"Gilham","year":"2016","journal-title":"Atherosclerosis"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626001893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626001893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:20:47Z","timestamp":1790094047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626001893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":60,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1359644626001893"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104784","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biochemical aspects of chromatin-modifying drugs","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104784","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104784"}}